For HIV-1–negative, at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1. See full Indication.

SAFETY

The safety of APRETUDE was studied in 2 international, multicenter, double-blind trials, HPTN 083 and HPTN 084. Get more details on the risks, adverse reactions, and discontinuation rates for APRETUDE below.

HPTN 083

HPTN 083

See the safety profile of APRETUDE as compared with a daily oral PrEP in cisgender men and transgender women who have sex with men and have evidence of high-risk behavior for HIV-1 infection

HPTN 084

HPTN 084

Review safety data for APRETUDE as compared with a daily oral PrEP in cisgender women at risk of acquiring HIV-1

HPTN=HIV Prevention Trials Network; PrEP=pre-exposure prophylaxis.

CBTWCNT210031